Results 21 to 30 of about 5,054 (206)

Axonal sensorimotor polyneuropathy after starting guselkumab

, 2022
Guselkumab is an IL-23 inhibitor that binds to the p19 subunit of IL-23 that is highly efficacious and well tolerated for the treatment of moderate-to-severe plaque psoriasis.
Muzamil A. Chisti, Issam Hamadah
core   +1 more source

Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes

Arthritis Research & Therapy, 2022
Objectives We compared the treatment effectiveness between guselkumab and adalimumab in patients with pustulotic arthro-osteitis (PAO). In addition, we performed peripheral blood immunophenotyping to elucidate the immunological background and analyzed ...
Masanobu Ueno, Ippei Miyagawa, Yusuke Miyazaki, Kentaro Hanami, Shunsuke Fukuyo, Satoshi Kubo, Shingo Nakayamada, Yoshiya Tanaka   +7 more
doaj   +1 more source

Guselkumab Modulates Differentially Expressed Genes in Blood of Patients With Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo‐Controlled Trials

ACR Open Rheumatology, 2023
Objective To evaluate gene expression in blood of patients with psoriatic arthritis (PsA) versus healthy controls and identify changes associated with guselkumab treatment.
Stefan Siebert, Kristen M. Sweet, Christopher T. Ritchlin, Elizabeth C. Hsia, Alexa P. Kollmeier, Xie L. Xu, Loqmane Seridi, Qingxuan Song, Sheng Gao, Warner Chen, Michelle Miron   +10 more
doaj   +1 more source

Effect of guselkumab on serum biomarkers in Japanese palmoplantar pustulosis patients in a randomized phase 3 study

JEADV Clinical Practice, 2023
Background It is reported that treatment of palmoplantar pustulosis (PPP) with guselkumab has greater improvement in clinical responses in terms of palmoplantar pustulosis area severity index (PPPASI) score. Here, we present the effect of guselkumab (100
Akimichi Morita, Yanqing Chen, Monica W. L. Leung, Naoko Kawashima, Tadashi Terui   +4 more
doaj   +1 more source

Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced

RMD Open, 2021
Objective Evaluation of the efficacy and safety of guselkumab, a human monoclonal antibody targeting the interleukin-23p19 subunit, in patients with psoriatic arthritis (PsA) through 1 year.Methods Adults who met ClASsification criteria for Psoriatic ...
Atul Deodhar, Shihong Sheng, Philip S Helliwell, Soumya D Chakravarty, Elizabeth C Hsia, Enrique R Soriano, Chetan S Karyekar, Wolf-Henning Boehncke, Prasheen Agarwal, Christopher T Ritchlin, Alexa P Kollmeier, Federico Zazzetti, Ramanand A Subramanian, Xie L Xu, Qing C Zuraw, Yusang Jiang, Bei Zhou, Yanli Zhuang, May Shawi   +18 more
doaj   +1 more source

A non-clinical comparative study of IL-23 antibodies in psoriasis

mAbs, 2021
Four antibodies that inhibit interleukin (IL)-23 are approved for the treatment of moderate-to-severe plaque psoriasis. Here, we present non-clinical data comparing ustekinumab, guselkumab, tildrakizumab and risankizumab with regard to thermostability ...
Li Zhou, Yibing Wang, Qi Wan, Fei Wu, Jeffrey Barbon, Robert Dunstan, Stephen Gauld, Mark Konrad, Laura Leys, Richard McCarthy, Marian Namovic, Christine Nelson, Gary Overmeyer, Denise Perron, Zhi Su, Leyu Wang, Susan Westmoreland, Jun Zhang, Rui Zhu, Geertruida Veldman   +19 more
doaj   +1 more source

Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study

Arthritis Research & Therapy, 2023
Background Guselkumab is a selective interleukin (IL)-23 inhibitor targeting the IL-23p19 subunit. In the phase 3b COSMOS trial, guselkumab demonstrated efficacy in treating participants with active psoriatic arthritis (PsA) and inadequate response (IR ...
Georg Schett, Warner Chen, Sheng Gao, Soumya D. Chakravarty, May Shawi, Frederic Lavie, Miriam Zimmermann, Mohamed Sharaf, Laura C. Coates, Stefan Siebert   +9 more
doaj   +1 more source

Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: a cohort study [version 2; peer review: 2 approved]

F1000Research, 2022
Background: Psoriasis is a chronic inflammatory disease which can impact quality of life. In the past decade multiple biologic treatments have been released with encouraging results. Guselkumab is a monoclonal antibody targeting IL-23p19.
Fiorella Vasquez Chinchay, Manuel Galán-Gutiérrez, Jose C. Armario-Hita, Amalia Pérez-Gil, Ricardo Ruiz-Villaverde, Lourdes Rodriguez-Fernandez-Freire   +5 more
doaj   +1 more source

Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis [PDF]

, 2022
Objectives: Evaluate the efficacy of guselkumab for the treatment of active psoriatic arthritis (PsA) utilizing composite indices. Methods: Data were pooled from the Phase 3 DISCOVER-1 (N=381) and DISCOVER-2 (N=739) studies.
Karyekar, Chetan S, Wang, Yanli, Xu, Xie, Helliwell, Philip S, Xu, Stephen, Contré, Christine, Xu, Xie L, Rahman, Proton, Mease, Philip J, Gossec, Laure, Karyekar, Chetan, Shawi, May, Ritchlin, Christopher, Coates, Laura C, Ritchlin, Christopher T, Helliwell, Philip, Kollmeier, Alexa, Kollmeier, Alexa P, Noël, Wim, Sheng, Shihong, Coates, Laura, Mease, Philip   +21 more
core   +3 more sources

Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis [PDF]

, 2022
Objective: The IL-23 p19-subunit inhibitor guselkumab has been previously compared with other targeted therapies for PsA through network meta-analysis (NMA).
Boehncke, Wolf-Henning, Peterson, Steve, Contré, Christine, Mease, Philip J, Rajalingam, Raji, Tam, Lai-Shan, Ritchlin, Christopher, Armstrong, Alison, McInnes, Iain B, Hassan, Fareen, McInnes, Iain B., Chakravarty, Soumya D, Mease, Philip   +12 more
core   +1 more source